Catalyst Wire Dossier Catalyst Wire Dossier

MASCT (Multiple Antigen Specific Cell Therapy)

· HRYZ Biotech Co.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MASCT (Multiple Antigen Specific Cell Therapy), covering 2017-10-18 to 2017-10-18. Get the full timeline:

Most recent: Clinical Trial Update: Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). [Phase 1, Phase 2]

See pricing